Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice
Open Access
- 9 June 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (6) , e0129327
Abstract
Chronic obstructive pulmonary disease (COPD) is a widespread disease, with no curative therapies available. Recent findings suggest a key role of NO and sGC-cGMP signaling for the pathogenesis of the disease. Previous data suggest a downregulation/inactivation of the cGMP producing soluble guanylate cyclase, and sGC stimulation prevented cigarette smoke-induced emphysema and pulmonary hypertension (PH) in mice. We thus aimed to investigate if the inhibition of the cGMP degrading phosphodiesterase (PDE)5 has similar effects. Results were compared to the effects of a PDE 4 inhibitor (cAMP elevating) and a combination of both. C57BL6/J mice were chronically exposed to cigarette smoke and in parallel either treated with Tadalafil (PDE5 inhibitor), Piclamilast (PDE4 inhibitor) or both. Functional measurements (lung compliance, hemodynamics) and structural investigations (alveolar and vascular morphometry) as well as the heart ratio were determined after 6 months of tobacco smoke exposure. In addition, the number of alveolar macrophages in the respective lungs was counted. Preventive treatment with Tadalafil, Piclamilast or a combination of both almost completely prevented the development of emphysema, the increase in lung compliance, tidal volume, structural remodeling of the lung vasculature, right ventricular systolic pressure, and right ventricular hypertrophy induced by cigarette smoke exposure. Single, but not combination treatment prevented or reduced smoke-induced increase in alveolar macrophages. Cigarette smoke-induced emphysema and PH could be prevented by inhibition of the phosphodiesterases 4 and 5 in mice.Keywords
This publication has 63 references indexed in Scilit:
- Sildenafil Potentiates Bone Morphogenetic Protein Signaling in Pulmonary Arterial Smooth Muscle Cells and in Experimental Pulmonary HypertensionArteriosclerosis, Thrombosis, and Vascular Biology, 2013
- Phosphodiesterase 4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in ratsAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2012
- Inducible NOS Inhibition Reverses Tobacco-Smoke-Induced Emphysema and Pulmonary Hypertension in MiceCell, 2011
- Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in miceBMC Pulmonary Medicine, 2010
- Elevated cyclic AMP and PDE4 inhibition induce chemokine expression in human monocyte-derived macrophagesProceedings of the National Academy of Sciences, 2009
- Effects of cigarette smoke on endothelial function of pulmonary arteries in the guinea pigRespiratory Research, 2009
- Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPDThorax, 2007
- Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchangeProceedings of the National Academy of Sciences, 2006
- NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialNature Reviews Drug Discovery, 2006
- Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular RemodelingCirculation, 2006